A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
Study of Talimogene Laherparepvec (T-VEC) and Radiation in Soft Tissue Sarcoma
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAS2351
U.S. Govt. ID: NCT02923778
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the effectiveness of preoperative radiation therapy used in combination with the immunostimulatory agent talimogene laherparepvec (T-VEC) to improve outcomes for patients with resectable soft tissue sarcomas, including soft tissue sarcoma (liposarcoma (excluding myxoid liposarcoma), leiomyosarcoma and undifferentiated pleomorphic sarcoma), arising in the trunk or chest wall.
This study is closed
Matthew Ingham, MD
Do You Qualify?
Are you 18 years or older? Yes No
Do you have a soft tissue sarcoma? Yes No
Do you agree to use contraception during study treatment and for 4 months after the end of treatment? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator